All In Biotech

Drug Trial Radar · NCT05836324

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

570

Planned (sponsor's estimate)

Start

Jul 24, 2023

Primary completion

May 3, 2029

Study completion May 3, 2029

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
May 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Conditions

  • Solid Tumors
  • Advanced Solid Tumors
  • Metastatic Solid Tumors

Interventions

  • INCA33890Drug

    INCA33890 will be administered at protocol defined dose.

  • bevacizumabDrug

    Bevacizumab will be administered at protocol defined dose.

  • FOLFIRIDrug

    FOLFIRI will be administered at protocol defined dose.

  • FOLFOXDrug

    FOLFOX will be administered at protocol defined dose.

  • CetuximabDrug

    Cetuximab will be administered at protocol defined dose.

  • ADG126Drug

    ADG126 will be administered at protocol defined dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Treatment Emerging Adverse Events (TEAEs)Time frame: Up to 2 years
  3. TEAEs leading to dose modification or discontinuationTime frame: Up to 2 years

Locations

39 sites in 9 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Cancer and Hematology Centers of Western Michigan-Start Midwest

    Grand Rapids, Michigan · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Nyu Langone Health - Long Island Hospital

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center

    New York, New York · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Lifespan Cancer Research Institute

    Providence, Rhode Island · Recruiting

  • University of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Not yet recruiting

  • Peking University People'S Hospital

    Beijing, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu)

    Hangzhou, China · Not yet recruiting

  • Rigshospitalet Uni of Hospital of Copenhagen

    Copenhagen, Denmark · Recruiting

  • Herlev Og Gentofte Hospital

    Herlev, Denmark · Recruiting

  • Odense University Hospital

    Odense C, Denmark · Recruiting

  • Vejle Hospital

    Vejle, Denmark · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan, Italy · Recruiting

  • Irccs Istituto Clinico Humanitas

    Rozzano, Italy · Recruiting

  • Centro Ricerche Cliniche Di Verona

    Verona, Italy · Recruiting

  • Kansai Medical University Hospital

    Hirakata, Japan · Recruiting

  • National Cancer Center Hospital

    Tokyo, Japan · Recruiting

  • The Cancer Institute Hospital of Jfcr

    Tokyo, Japan · Recruiting

  • Start Barcelona

    Barcelona, Spain · Recruiting

  • Hospital General Universitario Vall D Hebron

    Barcelona, Spain · Recruiting

  • Fundacion Jimenez Diaz University Hospital

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain · Recruiting

  • Istituto Oncologico Della Svizzera Italiana

    Bellinzona, Switzerland · Recruiting

  • Centre Hospitalier Universitaire Vaudois (Chuv)

    Lausanne, Switzerland · Recruiting

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland · Recruiting

  • Cambridge University Hospitals Nhs Foundation Trust

    Cambridge, United Kingdom · Recruiting

  • Guys and St Thomas Nhs Foundation Trust

    London, United Kingdom · Recruiting

  • Imperial College Healthcare Nhs Trust - Hammersmith Hospital

    London, United Kingdom · Recruiting

  • The Christie Nhs Foundation Trust Uk

    Manchester, United Kingdom · Recruiting

  • Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.